Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation – ATA (ATAI)

  • Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offering. 
  • See the SEC prospectus here.
  • The German company said it was looking to raise around $214.3 million through a U.S. IPO, targeting a valuation of about $2.3 billion.
  • The biotech startup, which explores the use of psychedelic treatments for mental health disorders, said it planned to sell around 14.29 million shares priced between $13 and $15 per share.
  • Launched in 2018, Atai has raised $362.3 million in cash so far.
  • Atai will be listed on the NASDAQ and will trade under the ticker symbol “ATAI.”
  • The company has built a pipeline of 10 development programs and six enabling technologies, each supported by its internal development and operational infrastructure.
  • One of its companies, Recognify Life Sciences, has initiated a Phase 2a trial in the U.S.
  • The company expects to initiate a Phase 2 trial for another program in 2021 and an additional three Phase 2 trials for other programs in 2022.
  • In April, the company filed to raise $100 million in an IPO.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Get Stock Market Insights, Technical Analysis, Live Market Data, ratings, insider trades
Compare items
  • Total (0)
Shopping cart